Tezspire (Tezepelumab) Side Effects
Tezepelumab is generally well-tolerated with a safety profile similar to placebo, though patients with parasitic infections require special consideration before initiating therapy.
Common Side Effects
The most frequently reported adverse events in clinical trials include 1, 2:
- Upper respiratory tract infections (common cold, nasopharyngitis)
- Pharyngitis (throat inflammation)
- Headache
- Injection site reactions
- Back pain
These adverse events occurred at similar frequencies in both tezepelumab and placebo groups across the PATHWAY and NAVIGATOR trials 1, 2.
Serious Adverse Events
The frequency and types of serious adverse events did not differ meaningfully between tezepelumab and placebo groups 2. In pooled analysis of 1,334 patients, the incidence of adverse events was similar between treatment groups 3.
Critical Safety Consideration: Parasitic Infections
Patients with known parasitic (helminth) infections must be treated for the infection before starting tezepelumab 4. This is a critical consideration because:
- Systemic corticosteroids (which may be used concurrently in severe asthma) can worsen conditions like Strongyloides infection 4
- The guideline specifically warns about consideration of coexisting conditions that could be worsened, including parasitic infections, particularly Strongyloides 4
- If a patient develops a parasitic infection during treatment and does not respond to anti-helminth therapy, tezepelumab should be discontinued until the infection resolves
Monitoring Recommendations
For patients with severe asthma receiving tezepelumab:
- Screen for parasitic infections before initiation, especially in patients with risk factors (travel history, eosinophilia, geographic exposure) 4
- Monitor for signs of infection during treatment, as upper respiratory infections are common 1
- Assess asthma control regularly, as worsening asthma was reported as an adverse event in trials 1
- Do not discontinue existing asthma controller medications abruptly when starting tezepelumab
Comparative Safety Profile
Unlike some other biologic therapies, tezepelumab demonstrated consistent safety across all asthma phenotypes including eosinophilic, allergic, type 2-low, and oral corticosteroid-dependent asthma 5, 3. The medication reduced exacerbations by 56-71% across phenotypes without increasing adverse events 2.
Contraindications and Precautions
- Not for treatment of acute bronchospasm or status asthmaticus (use rescue medications instead)
- Hypersensitivity reactions are possible with any biologic therapy, though not specifically highlighted in the trial data 2
- Pregnancy and lactation: Limited data available; use clinical judgment regarding risk-benefit